Filed Pursuant to Rule 424(b)(3)
Registration No. 333-263456
PROSPECTUS SUPPLEMENT NO. 1
(To the Prospectus dated
May 19, 2022)
Up to 48,503,325 Shares of Common Stock
This prospectus supplement supplements the prospectus, dated May 19, 2022 (the Prospectus), which forms a part of our
registration statement on Form S-1 (No. 333-263456). This prospectus supplement is being filed to update and supplement the information in the Prospectus with certain information contained in our Current
Report on Form 8-K filed with the Securities and Exchange Commission on May 20, 2022 (the Current Report). Accordingly, we have attached the Current Report to this prospectus supplement.
The Prospectus and this prospectus supplement relate to the offer and resale of up to 48,503,325 shares of our common stock, $0.0001 par value
per share, by Tumim Stone Capital LLC (Tumim).
The shares of common stock being offered by Tumim have been and may be
issued pursuant to the common stock purchase agreement dated February 11, 2022 that we entered into with Tumim (the Purchase Agreement). We are not selling any securities under this prospectus and will not receive any of the
proceeds from the sale of our common stock by Tumim. However, we may receive up to $175.0 million in aggregate gross proceeds from sales of our common stock to Tumim that we may make under the Purchase Agreement, from time to time after the
date of this prospectus.
The common stock and Warrants are listed on the New York Stock Exchange (NYSE) under the
symbols IRNT and IRNT.WS, respectively. On May 20, 2022, the last reported sales price of our common stock on NYSE was $2.67 per share and the last reported sales price of our Warrants was $0.4338 per warrant.
This prospectus supplement should be read in conjunction with the Prospectus, including any amendments or supplements thereto, which is to be
delivered with this prospectus supplement. This prospectus supplement is qualified by reference to the Prospectus, including any amendments or supplements thereto, except to the extent that the information in this prospectus supplement updates and
supersedes the information contained therein.
This prospectus supplement is not complete without, and may not be delivered or utilized
except in connection with, the Prospectus, including any amendments or supplements thereto.
We are an emerging growth company
as defined under U.S. federal securities laws and, as such, have elected to comply with reduced public company reporting requirements. The Prospectus complies with the requirements that apply to an issuer that is an emerging growth company.
Investing in our securities involves a high degree of risk. You should review carefully the risks and uncertainties described in the
section titled Risk Factors beginning on page 8 of the Prospectus and under similar headings in any amendments or supplements to the Prospectus.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities, or
passed upon the accuracy or adequacy of this prospectus supplement or the Prospectus. Any representation to the contrary is a criminal offense.
Prospectus Supplement dated May 23, 2022